Hikma Pharmaceuticals USA
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.5Mgeneral payments (2019-2025)
$283Kresearch payments (2019-2025)
12,481clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Ryaltris $272K associated (2023-2025)
- Ibrutinib $154K associated (2023-2025)
- Abiraterone $148K associated (2023-2025)
- Lenalidomide $125K associated (2023-2025)
- Dasatinib $86K associated (2023-2025)
- Kloxxado $63K associated (2023-2025)
- Combogesic IV $30K associated (2023-2025)
- Dexilant $26K associated (2023-2025)
- Mitigare $8,753 associated (2023-2025)
- Cresemba $7,250 associated (2023-2025)
- Baxdela $5,250 associated (2023-2025)
- Zidovudine $2,872 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Paul Hogya | South Lebanon, OH | Emergency Medicine | $468,273.00 |
| Elias Jabbour | Houston, TX | Hematology & Oncology | $259,297.37 |
| Hagop Kantarjian | Houston, TX | Medical Oncology | $118,237.17 |
| Tapan Kadia | Houston, TX | Internal Medicine | $70,828.42 |
| Ralph Defronzo | San Antonio, TX | Endocrinology, Diabetes & Metabolism | $66,846.37 |
| David Deyhimy | Laguna Hills, CA | Anesthesiology | $62,750.25 |
| Naval Daver | Houston, TX | Hematology & Oncology | $56,993.38 |
| Rami Komrokji | Tampa, FL | Hematology (Internal Medicine) | $55,211.91 |
| Nuhad Ibrahim | Houston, TX | Medical Oncology | $50,987.88 |
| Debra Tashlein | Orange, CT | Women'S Health (Nurse Practitioner) | $47,143.44 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.